Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells.
The objective of this study was to examine the expression of Toll-like receptor 3 (TLR3) by human corneal epithelial cells (HCECs) and to determine whether exposure to the TLR3 agonist polyinosinic-polycytidylic acid [poly(I:C)] induces an antiviral response in these cells. Fluorescence-activated cell sorter (FACS) analysis revealed TLR3 to be constitutively expressed and distributed intracellularly in HCECs. Stimulation of HCECs with the TLR3 agonist poly(I:C) induced the activation of nuclear factor (NF)-kappaB and production of the proinflammatory cytokine interleukin (IL)-6 and the chemokine IL-8. Upon exposure to poly(I:C), HCECs initiated a potent antiviral response resulting in an increase of interferon (IFN)-beta mRNA expression (7-fold). Poly(I:C) stimulation also up-regulated mRNA expression of the antiviral chemokine IFN-gamma inducible protein 10 (IP10), myxovirus resistance gene A and 2',5'-oligoadenylate synthetase (5-, 10- and 9-fold, respectively), and secretion of IP10. These responses were also induced by exogenously added type 1 IFNs, but could not be blocked by pretreatment of the cells with anti-TLR3 monoclonal antibody, suggesting that the receptor was not expressed on the cell surface. Furthermore, incubation of HCECs with an endosomal acidification inhibitor, chloroquine, markedly inhibited poly(I:C)-mediated IFN-beta expression in HCECs. These results suggest that corneal epithelial cells are important sentinels of the corneal innate immune system against viral infection, and that stimulation of TLR3 can induce the expression of key proinflammatory cytokines and chemokines and antiviral genes that help in the defence of the cornea against viral infection.
Kumar
Ashok
A
Kresge Eye Institute/Department of Ophthalmology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Zhang
Jing
J
Yu
Fu-Shin X
FS
D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D015153:Blotting, Western; D002460:Cell Line; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000096:biosynthesis / Q000235:genetics; D019573:Epithelium, Corneal / Q000187:drug effects / Q000276:immunology / Q000821:virology*; D019204:GTP-Binding Proteins / Q000378:metabolism; D005786:Gene Expression Regulation / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology; D016899:Interferon-beta / Q000276:immunology / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D064547:Myxovirus Resistance Proteins; D016328:NF-kappa B / Q000378:metabolism; D011070:Poly I-C / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics; D051196:Toll-Like Receptor 3 / Q000819:agonists* / Q000378:metabolism
D000998:Antiviral Agents; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D016898:Interferon-alpha; D015850:Interleukin-6; D016209:Interleukin-8; D064547:Myxovirus Resistance Proteins; D016328:NF-kappa B; D012333:RNA, Messenger; D051196:Toll-Like Receptor 3; D016899:Interferon-beta; D015088:2',5'-Oligoadenylate Synthetase; D019204:GTP-Binding Proteins; D011070:Poly I-C